Isoflavone intervention and its impact on bone mineral density in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials
Authors' conclusion
This systematic review and meta-analysis suggests that isoflavone interventions, especially those containing genistein of at least 50 mg/day, can effectively enhance BMD in postmenopausal women.
Study context
- Population
- Postmenopausal women; RCTs from PubMed, Embase, Scopus and Cochrane Library up to April 20, 202363 RCTs
- Participants
- 4,754 vs 4,272
- Comparison
- Isoflavone interventions vs placebo
- Isoflavonen = 4,754
- Placebon = 4,272reference
- Outcome
- BMD (main effect estimates as MD)
Methodological detailsrandom-effects model, RoB2 risk of bias assessment
- Random-effects model
- RoB2 risk of bias assessment
Pooled result
As reported in the abstract
BMD
Each group vs placeboEstimate (95% CI)P value
Isoflavone
MD (lumbar spine) 0.0175 g/cm²(0.0088–0.0263)
P < 0.0001Isoflavone
MD (femoral neck) 0.0172 g/cm²(0.0046–0.0298)
P = 0.0073Isoflavone
MD (distal radius) 0.0138 g/cm²(0.0077–0.0198)
P < 0.0001Further pooled results
Bone mineral density (BMD) by subgroup (duration, genistein dose)
- Isoflavone effective for improving BMD when duration ≥ 12 months and when containing genistein ≥50 mg/day
Original publication
Isoflavone intervention and its impact on bone mineral density in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Osteoporos Int. Published 25 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →